NASDAQ:CRDF Cardiff Oncology (CRDF) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free CRDF Stock Alerts $4.07 +0.08 (+2.01%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$3.98▼$4.1350-Day Range$1.67▼$5.9152-Week Range$0.94▼$6.42Volume516,205 shsAverage Volume1.47 million shsMarket Capitalization$181.85 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cardiff Oncology alerts: Email Address Cardiff Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside158.0% Upside$10.50 Price TargetShort InterestBearish8.93% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.98) to ($1.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.74 out of 5 starsMedical Sector839th out of 913 stocksBiological Products, Except Diagnostic Industry137th out of 145 stocks 3.5 Analyst's Opinion Consensus RatingCardiff Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCardiff Oncology has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.93% of the outstanding shares of Cardiff Oncology have been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 17.01%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRDF. Previous Next 0.8 News and Social Media Coverage News SentimentCardiff Oncology has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cardiff Oncology this week, compared to 1 article on an average week.Search InterestOnly 15 people have searched for CRDF on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -46% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.30% of the stock of Cardiff Oncology is held by insiders.Percentage Held by InstitutionsOnly 16.29% of the stock of Cardiff Oncology is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cardiff Oncology are expected to decrease in the coming year, from ($0.98) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiff Oncology is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiff Oncology is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Cardiff Oncology Stock (NASDAQ:CRDF)Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Read More CRDF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRDF Stock News HeadlinesApril 25, 2024 | globenewswire.comCardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateApril 9, 2024 | investorplace.comElection Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?April 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 8, 2024 | globenewswire.comCardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical StudyMarch 27, 2024 | msn.combluebird bio falls as accounting errors force restatementsMarch 21, 2024 | investorplace.comFinding the Next Big Winners: 3 Stocks You Can Snag for Under $5March 16, 2024 | finance.yahoo.comREGN Mar 2024 1010.000 putMarch 16, 2024 | finance.yahoo.comREGN Mar 2024 982.500 callApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 15, 2024 | finance.yahoo.comCRDF Apr 2024 2.500 callMarch 15, 2024 | finance.yahoo.comCRDF Nov 2024 10.000 putMarch 15, 2024 | finance.yahoo.comCRDF Apr 2024 5.000 callMarch 14, 2024 | finance.yahoo.comREGN Mar 2024 992.500 callMarch 8, 2024 | seekingalpha.comCardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)March 6, 2024 | globenewswire.comCardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024March 3, 2024 | finance.yahoo.comCardiff Oncology Full Year 2023 Earnings: Beats ExpectationsMarch 2, 2024 | seekingalpha.comCardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comCardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | msn.comNasdaq Surges 100 Points; ISM Manufacturing PMI Falls In FebruaryMarch 1, 2024 | msn.comSmall Cap-Cardiff Oncology Outlines Data From Discontinued Colorectal Cancer Trial, Stock SoarsMarch 1, 2024 | finance.yahoo.comCardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial ResultsMarch 1, 2024 | uk.finance.yahoo.comQ4 2023 Cardiff Oncology Inc Earnings CallMarch 1, 2024 | finanznachrichten.deCardiff Oncology, Inc.: Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRCMarch 1, 2024 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Cardiff Oncology (CRDF)February 29, 2024 | globenewswire.comCardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateFebruary 29, 2024 | globenewswire.comCardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRCFebruary 29, 2024 | globenewswire.comCardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)See More Headlines Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/26/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CRDF CUSIPN/A CIK1213037 Webcardiffoncology.com Phone(858) 952-7570FaxN/AEmployees31Year Founded1999Price Target and Rating Average Stock Price Target$10.50 High Stock Price Target$14.00 Low Stock Price Target$7.00 Potential Upside/Downside+158.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,440,000.00 Net Margins-8,492.01% Pretax Margin-8,492.01% Return on Equity-50.13% Return on Assets-44.31% Debt Debt-to-Equity RatioN/A Current Ratio7.41 Quick Ratio7.41 Sales & Book Value Annual Sales$490,000.00 Price / Sales371.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book2.61Miscellaneous Outstanding Shares44,680,000Free Float41,862,000Market Cap$181.85 million OptionableOptionable Beta1.94 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Mark Erlander Ph.D. (Age 64)CEO & Director Comp: $2.43MMr. James E. Levine (Age 53)Chief Financial Officer Comp: $1.57MDr. Tod Smeal Ph.D. (Age 59)Chief Scientific Officer? Comp: $2.69MMs. Elizabeth AndersonVP of Finance & AdministrationMs. Brigitte LindsaySenior Vice President of FinanceMr. Charles Monahan R.Ph.Senior VP of Regulatory AffairsDr. Fairooz Kabbinavar FACP (Age 66)M.D., Chief Medical Officer More ExecutivesKey CompetitorsINmune BioNASDAQ:INMBAcumen PharmaceuticalsNASDAQ:ABOSInnate PharmaNASDAQ:IPHAOptheaNASDAQ:OPTKodiak SciencesNASDAQ:KODView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 11,200 shares on 4/25/2024Ownership: 0.000%Assenagon Asset Management S.A.Bought 252,982 shares on 4/24/2024Ownership: 0.566%PFG Investments LLCBought 10,001 shares on 4/22/2024Ownership: 0.022%Gary W PaceBought 30,000 shares on 12/19/2023Total: $41,100.00 ($1.37/share)View All Insider TransactionsView All Institutional Transactions CRDF Stock Analysis - Frequently Asked Questions Should I buy or sell Cardiff Oncology stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRDF shares. View CRDF analyst ratings or view top-rated stocks. What is Cardiff Oncology's stock price target for 2024? 2 analysts have issued 12 month target prices for Cardiff Oncology's stock. Their CRDF share price targets range from $7.00 to $14.00. On average, they expect the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 158.0% from the stock's current price. View analysts price targets for CRDF or view top-rated stocks among Wall Street analysts. How have CRDF shares performed in 2024? Cardiff Oncology's stock was trading at $1.48 at the beginning of the year. Since then, CRDF shares have increased by 175.0% and is now trading at $4.07. View the best growth stocks for 2024 here. Are investors shorting Cardiff Oncology? Cardiff Oncology saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 3,990,000 shares, an increase of 17.0% from the March 31st total of 3,410,000 shares. Based on an average daily volume of 1,780,000 shares, the days-to-cover ratio is currently 2.2 days. View Cardiff Oncology's Short Interest. When is Cardiff Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CRDF earnings forecast. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:CRDF) announced its earnings results on Thursday, February, 29th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.05. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.08 million. Cardiff Oncology had a negative trailing twelve-month return on equity of 50.13% and a negative net margin of 8,492.01%. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA). Who are Cardiff Oncology's major shareholders? Cardiff Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.57%), Simplex Trading LLC (0.00%) and PFG Investments LLC (0.02%). Insiders that own company stock include Gary W Pace, James E Levine, Lale White, Mark Erlander and Renee P Tannenbaum. View institutional ownership trends. How do I buy shares of Cardiff Oncology? Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRDF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
